About SR One

SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.

Investment Details

Investment Range
Not specified
Investment Stage
Various stages
Industry Focus
Finance, Healthcare, VR/AR (+1 more)
Investor Type
Venture Capital

Investment Focus

Focus Areas
Healthcare VR/AR Finance Financial Services
Investment Stages
Early Stage, Early Stage Venture, Late Stage Venture, Post-Ipo, Private Equity, Seed, Venture